The causal relationship between gastro-esophageal reflux disease and idiopathic pulmonary fibrosis: A bidirectional two-sample Mendelian randomization study

Carl J Reynolds[1], Fabiola Del Greco M[2], Richard J Allen[3], Carlos Flores[4,5,6,7], R Gisli Jenkins[1], Toby M Maher[1,8], Philip L Molyneaux[1], Imre Noth[9], Justin M Oldham[10], Louise V Wain[3,11], Jiyuan An[12], Jue-Sheng Ong[13], Stuart MacGregor[13], Tom A. Yates[14], Paul Cullinan[1], Cosetta Minelli[1]

1. National Heart and Lung Institute, Imperial College London, London, UK
2. Institute for Biomedicine, Eurac Research, Bolzano, Italy
3. Department of Health Sciences, University of Leicester, Leicester, UK
4. Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
5. CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
6. Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife, Spain

7. Faculty of Health Sciences, University of Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain
8. Keck School of Medicine, The University of Southern California, Los Angeles, CA, USA
9. Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville VA
10. Department of Internal Medicine; Division of Pulmonary and Critical Care Medicine, University of Michigan
11. National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, UK
12. Centre for Agriculture and the Bioeconomy Faculty of Science Queensland University of Technology, Brisbane, Australia
13. Population Health Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
14. Division of Infection and Immunity, Faculty of Medicine, University College London, London, UK.

Abstract 243 words
Text 2732 words

Abstract

Background Gastro-esophageal reflux disease (GERD) is associated with idiopathic pulmonary fibrosis (IPF) in observational studies. It is not known if this association arises because GERD causes IPF, or IPF causes GERD, or because of confounding by factors, such as smoking, associated with both GERD and IPF. We used bidirectional Mendelian randomisation (MR), where genetic variants are used as instrumental variables to address issues of confounding and reverse causation, to examine how, if at all, GERD and IPF are causally related.

Methods and results A bidirectional two-sample MR was performed to estimate the causal effect of GERD on IPF risk, and of IPF on GERD risk, using genetic data from the largest GERD (78,707 cases and 288,734 controls) and IPF (4,125 cases and 20,464 controls) genome-wide association meta-analyses currently available. GERD increased the risk of IPF, with an odds ratio (OR) of 1.6 (95% Confidence Interval, CI: 1.04-2.49; p=0.032). There was no evidence of a causal effect of IPF on the risk of GERD, with an OR of 0.99 (95%CI: 0.97-1.02; p=0.615).

Conclusion We found that GERD increases the risk of IPF, but found no evidence that IPF increases the risk of GERD. GERD should be considered in future studies of IPF risk, and interest in it as a potential therapeutic target should be renewed. The mechanisms

underlying the effect of GERD on IPF should also be investigated.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterised by usual interstitial pneumonia pattern on CT thorax or biopsy in the absence of a recognised cause. [1] The incidence in Europe and North America is 3-9 per 100,000 person-years [2] and the prognosis is poor, with a median survival of three years. [3,4] IPF is thought to result from epithelial injury in the distal airways, in a susceptible host, initiating a dysregulated repair process. [5] Environmental contributions to IPF are not well understood but several exposures have been posited as causal, these include smoking, diabetes mellitus, and gastro-esophageal reflux disease (GERD).

GERD is defined by non-physiological aspiration of gut contents associated with troublesome symptoms and/or complications such as esophagitis. [6] GERD has been associated with IPF in observational studies [7] but it is not known if GERD causes an increased risk of IPF. The observed association might be due to confounding by factors, such as smoking, associated with both GERD and IPF. The association could also result from reverse causation, with IPF causing an increased risk of GERD rather than vice-versa. [8] This is plausible given that reduced lung compliance in IPF can lead to more negative intrathoracic pressures and reflux events are inversely correlated with inspiratory thoracic pressures. [9, 10]

Unlike observational associations, genetic associations are not affected by classical confounding or reverse causation, as genes are randomly allocated at conception. A Mendelian randomisation (MR) approach that uses genetic variants known to affect GERD as its proxies (instrumental variables) can therefore provide indirect evidence for a causal effect of GERD on the risk of IPF, if its underlying assumptions hold. [11,12] Likewise, using genetic variants known to affect IPF risk as its proxies, the same approach can provide indirect evidence for a causal effect of IPF on the risk of GERD.

In this paper we describe a bidirectional, two-sample MR study to estimate the causal effect of GERD on the risk of IPF, and of IPF on GERD risk. We used data from the largest available genome-wide association meta-analyses for both GERD [13] and IPF. [14]

Page Break

Methods

Genetic data

For both our analyses of the effect of GERD on IPF risk, and of the effect of IPF on GERD risk, we used two-sample MR where summary statistics (effect estimates and standard errors) for the gene-exposure (G-X) and gene-outcome (G-Y) associations were obtained from separate studies. A graphical overview of the two MR analyses is provided in Figure 1.

For the MR of the effect of GERD on IPF risk, instruments were selected from the largest available genome-wide association study (GWAS) meta-analysis on GERD by Ong et al.

[13] For each instrument (Single Nucleotide Polymorphism, SNP), summary statistics of the G-X association (expressed as log OR for GERD) were obtained from the replication stage of Ong et al. [13] Summary statistics of the G-Y association (log OR for IPF) were obtained from the authors of the GWAS meta-analysis on IPF. [14]

Similarly, for the MR of the effect of IPF on GERD risk, instruments were selected from the largest available GWAS meta-analysis on IPF by Allen et al. [14]. For each SNP, summary statistics of the G-X association (log OR for IPF) were obtained from this GWAS, while summary statistics of the G-Y association (log OR for GERD) were obtained from the authors of the GWAS meta-analysis on GERD. [13]

MR methods

Here we provide an overview of the MR methods used, with a more detailed description of these methods, their underlying assumptions, relevant references and the code used for the analyses reported in Supplementary Methods.

We estimated the causal effect of GERD on IPF risk (Figure 1a) and of IPF on GERD risk (Figure 1b) by first deriving SNP-specific MR estimates using the Wald estimator (G-Y divided by G-X), and then pooling them using inverse-variance weighted, fixed-effect meta-analysis (IVW-FE).

We used the IVW-FE method for our main MR analyses as this is the most powerful one, but it assumes absence of pleiotropy, i.e. variants chosen as instruments for the exposure cannot affect the outcome through any other independent pathways. Pleiotropy can bias MR findings, and we therefore investigated its possible presence through assessment of the heterogeneity in the MR estimates across SNPs, using the I^2 index and Cochran's Q heterogeneity test.

In the presence of pleiotropy, possible pleiotropic SNPs were identified graphically based on their contribution to the overall heterogeneity (Cochran's Q statistic), and we repeated the IVW-FE analysis after removing the pleiotropic SNPs. We also performed MR analyses on all SNPs using methods that can account for pleiotropy under different assumptions about its nature. In particular, we considered the following methods: inverse variance weighted random-effect (IVW-RE); Weighted Median (WMe); Weighted Mode-based (WMo); and MR-Egger (MRE), with the simulation extrapolation (SIMEX) method to correct for measurement error (dilution bias) used if needed.

Results

Demographic data for the cohorts used is provided in Table 1 and described below.

Effect of GERD on IPF risk

The GWAS on GERD by Ong et al. [13] identified 59 independent genome-wide significant (p<5x10^{-8}) SNPs, based on a total sample of 78,707 GERD cases and 288,734 controls, with replication of findings in 462,753 cases and 1,484,025 controls. [13] The sample was almost entirely of White European ancestry. GERD cases were defined by having one or

more of a GERD ICD10 code, GERD self-report, or use of GERD medication.

Of the 59 SNPs, two were missing in the IPF GWAS meta-analysis dataset and a proxy (i.e. SNP with linkage disequilibrium, LD, $r^2 \geq 0.8$ with the SNP of interest) was used instead (Supplementary Table 1). All SNPs used in the MR analysis were "strong" instruments with an F statistic>10 [15], where the F statistic is a function of both magnitude and precision of the SNP's effect on GERD. [16] Individual F statistics ranged from 12 to 81 (Supplementary Table 1).

This MR analysis showed that GERD increases the risk of IPF, with an odds ratio (OR) of 1.61 (95% Confidence Interval, CI: 1.04-2.49; p=0.032).

There was no statistical evidence of pleiotropy, with an I^2 of 0% (95%CI: 0-31%), and, a heterogeneity p-value of 0.52.

Effect of IPF on GERD risk

The GWAS meta-analysis on IPF by Allen et al. [14] included three previously published studies (Chicago, Colorado, UK) [17–19] plus an unpublished study including independent case-control studies from the US, UK, and Spain (UUS), and a study of clinical trial subjects, the Genentech study. The Genentech study consisted of cases from three IPF clinical trials and controls from four non-IPF clinical trials.

The GWAS meta-analysis included a total of 4,125 IPF cases and 20,464 controls of White European ancestry. IPF cases were defined using the joint American Thoracic Society and European Respiratory Society guidelines. [20] [21] [1]

Of the 19 SNPs, 15 were missing in the GERD GWAS meta-analysis database. For nine a proxy (LD r^2>0.8) was used (Supplementary Table 2). Data for the remaining six, for which a satisfactory proxy could not be identified, were obtained from the authors. Individual F statistics ranged from 30 to 1,721 (Supplementary Table 2).

The MR analysis showed no evidence of a causal effect of IPF on the risk of GERD, with an OR of 0.999 (95%CI: 0.997-1.001; p=0.245).

We found evidence of pleiotropy, with an I^2 of 63% (95%CI: 40%-77%), and a heterogeneity p-value of 0.00016. We identified 5 possible pleiotropic SNPs, shown in Figure 3. After removing them, there was no evidence of residual pleiotropy (I2 of 0%; heterogeneity p-value of 0.944), and the results remained null (OR of 0.998; 95%CI: 0.996-1.001; p=0.137). Similar null findings were obtained when using robust methods that adjust for pleiotropy, as shown in Figure 2.

Discussion

We undertook a bidirectional two-sample MR study to investigate the causal relationship

between GERD and IPF. We found evidence of a causal effect of GERD on IPF, but not of IPF on GERD.

The odds of IPF were 1.6 times higher in the presence of GERD (95%CI: 1.04-2.49; p=0.032). Previous evidence for the association of GERD and IPF arises from observational studies where it has not been possible to confidently make causal inferences because of the potential for residual confounding and reverse causation. A case-control study of 17 consecutive biopsy-proven IPF patients and eight controls with non-IPF ILD at a US tertiary ILD centre [22], which involved ambulatory esophageal pH monitoring and a GERD symptom questionnaire, found that the majority of IPF, but not non-IPF ILD, patients had abnormal esophageal acid exposure which was usually clinically silent. A similar pattern was seen in a later study of 65 consecutive IPF patients at the same centre, which used 133 consecutive asthma patients referred to a gastrointestinal motility clinic as controls. [23] A systematic review of IPF comorbidities found 23 studies that reported prevalence of GERD in IPF patients. The majority of the studies were small, with fewer than 50 patients, and they used a variety of case definitions for GERD. [24] Study estimates varied widely, from 0 to 94%, but most were around 30%. [24] This is higher than prevalence estimates for the general population; GERD global population prevalence increases with age and peaks at 18% for people aged 75-79. [25] A recent meta-analysis of 18 case-control studies [7] comprising 3206 patients with IPF and 9368 controls, found the odds of IPF was 2.94 time higher in people with GERD (95% CI: 1.95-4.42), but with high heterogeneity across studies (I^2 = 86%; heterogeneity p-value<0.00001). The authors reported that confounding by smoking was likely for two reasons. First, a post-hoc meta-regression that controlled for smoking found the association was no longer significant (OR: 0.66; 95% CI: 0.34-1.27). Second, the effect sizes tended to be larger in studies where a higher proportion of cases, and a lower proportion of controls, smoked. There was significant correlation between the ratio of the proportion of smokers (and ex-smokers) in IPF cases over the proportion in controls and the log odds ratio for the association of GERD and IPF. Our findings using an MR approach overcome confounding by smoking and any other (known or unknown) confounding of observational analyses to indicate a causal effect of GERD on IPF risk.

The underlying mechanism explaining how GERD may increase IPF risk is unknown, however, aspiration of gastric contents can cause chemical pneumonitis or aspiration pneumonia. [26] One study of GERD in IPF included bronchoalveolar lavage (BAL) and compared 21 IPF patients with 20 non-IPF ILD patients and 16 patients undergoing bronchoscopy for other diseases. BAL fluid was analysed for the presence of pepsin and bile acids. Pepsin and/or bile acids were present in 62% of IPF patients compared with 25% of non-IPF ILD patients, and were absent for all patients undergoing bronchoscopy for other diseases. [27]

While direct chemical or bacterial epithelial insult may initiate or promote fibrosis another possibility is by indirect means. For example, GERD may increase IPF risk through airway acidification secondary to aspiration disrupting MUC5B function and impairing innate immunity. The *MUC5B* promoter variant rs35705950, which increases airway expression of MUC5B, is the strongest common identified risk factor for IPF. The odds of developing pulmonary fibrosis are 5 times higher for individuals carrying one copy of the disease allele, rising to 20 times higher for individuals with two copies, when compared with individuals

carrying no copies of the disease allele. The frequency of the disease allele is around 9% in European ancestry populations. [28,29] While MUC5B is undoubtedly important for IPF risk, the mechanisms by which increased airway MUC5b expression increases IPF risk are not well understood. In evolutionary terms, it is a highly conserved airway mucin that plays a key role in antimicrobial host defence [30] and has been shown to reduce mucosal bacterial load and to promote mucosal microbial diversity. [31] The structure, and function, of MUC5B is pH dependent [32] [33] and may be disrupted by acidification of the airway secondary to GERD. In IPF, there are higher airway bacterial loads and reduced microbial diversity compared with COPD patients and healthy controls [34] and this is associated with disease progression. [35]

The theoretical possibility of reverse causation, whereby the association between IPF and GERD is driven by IPF, rather than GERD, is well described. [36] Restrictive lung disease may distort the esophageal gastric junction and predispose to hiatus hernia. Indeed, hiatus hernia has been observed to be more common in IPF than in patients with asthma or COPD. [37] Reduced lung compliance in IPF can result in increasingly negative intrathoracic pressures being required for inspiration and an increased gastro-oesophageal pressure gradient. [38] Reflux events generally occur during inspiration and are inversely correlated with inspiratory thoracic pressures. [9] [10] Other mechanical factors that might contribute to GERD secondary to IPF are reduced esophageal body motility, lower basal lower esophageal sphincter pressure, and delayed gastric emptying. [36] We therefore investigated the possibility of causality in both directions using a bidirectional MR approach, but we found no evidence of a causal effect of IPF on GERD risk. In this MR analysis of the effect of IPF on GERD, however, pleiotropy was observed and five possible pleiotropic SNPs identified, but the result remained null after removing them and when adjusting for pleiotropy using robust methods.

A major strength of our MR work, in contrast to previous observational work examining GERD-IPF relations, is that MR is not affected by classical confounders, such as smoking, or by reverse causation. Our work therefore overcomes these limitations of observational studies to establish GERD as a risk factor for IPF.

Our study also has some limitations. One major problem of MR is that while it is not vulnerable to classical confounding or reverse causation it is affected by pleiotropy. We found evidence for pleiotropy in our MR of IPF on GERD but adjusting for it did not alter our results. Our study had more power for finding an effect of GERD on IPF than IPF on GERD as a consequence of GERD being more common, and there being many more genotyped GERD patients than IPF patients available. We cannot exclude that a small effect of IPF on GERD might be found in a future MR study performed on data from a larger IPF sample. Finally, participants contributing to the GWAS meta-analyses used were almost entirely of White European ancestry, limiting generalisability to other groups.

GERD should be taken into account in future studies of IPF risk and interest in it as a potential therapeutic target should be renewed. Treatment of GERD is not well established to be of benefit in IPF; a recent systematic review found no evidence that treating GERD with antacids, or fundoplication, improved outcomes in IPF. [39] There is also potential for harm, since adverse events including increased risk of bacterial infection have been associated with antacid use. [39] Consequently, international guidelines have been updated

to include a conditional recommendation against, rather than for, antacid treatment in IPF. Uncertainty remains due to a lack of adequately powered well designed randomised controlled trials (RCT) in this area, though one is now underway. [40]

We have assessed the risk of developing IPF in GERD, which is not amenable to indirect assessment by an RCT of GERD treatment, given how rare IPF is an outcome. It could be that GERD has also an independent effect on IPF disease progression; this could be investigated in a future study when sufficient genetic data becomes available. Understanding the mechanism for increased IPF risk in GERD is now necessary to understand which patients may benefit from existing treatments, and for identification of novel therapeutic targets.

Conclusion

By means of a bidirectional two-sample MR study we have overcome limitations inherent to observational studies and shown that GERD causes an increased risk of IPF, while we found no evidence that IPF causes an increased risk of GERD. GERD should be considered in future studies of IPF risk, and interest in it as a potential therapeutic target should be renewed. The mechanisms underlying the effect of GERD on IPF should also be investigated.

Conflict of interest

The authors declare that they have no conflicts of interest.

Funding

TAY is an NIHR Clinical Lecturer supported by the National Institute for Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

R J Allen is an Action for Pulmonary Fibrosis Mike Bray Research Fellow. L V Wain holds a GSK/Asthma + Lung UK Chair in Respiratory Research (C17-1). R G Jenkins, L Wain and R Allen are supported by the Medical Research Council (MR/W014491/1). The research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health.

Tables and Figures

Table 1: Summary information for the studies contributing to the data used in both MR analyses.

Study		N	Age (Mean (SD))	Sex (% Males)	Ever smokers %	Genotyping array	Imputation panel
			GERD				
UK	Cases	75720	59	_	_		
	Controls	278565	57	46	41	Affymetrix UK BiLEVE array	HRC
Australia	Cases	2987	56.5	_	_	Illumina Global Screening	
	Controls	10169	56	46	54	Array	HRC
			IPF				
Chicago	Cases	541	68(3)	71	72		HRC
	Controls	542	63(7.5)	47	42	Affymetrix 6.0 SNP array	
Colorado	Cases	1515	66(9.5)	68	_	Illumina Human 660W Quad	
	Controls	4683	_	49	_	BeadChip	HRC
UK	Cases	612	70(8.4)	71	73	Affymetrix UK BiLEVE array	
	Controls	3366	65(5.5)	70	70	Affymetrix UK BiLEVE and UK Biobank arrays	HRC
UUS	Cases	793	69(8.1)	75	69	Affymetrix UK Biobank and Spain Biobank arrays	
	Controls	9999	58(7.8)	72	68	Affymetrix UK BiLEVE and UK Biobank arrays	HRC
Genentech	Cases	664	68(7.5)	74	67	HiSeq X Ten platform	
	Controls	1874	56(9.3)	27	18	(Illumina)	

Figure 1: Overview of our two-sample MR analysis of: **a)** GERD on IPF risk; **b)** IPF on GERD risk. G-X: gene-exposure association; G-Y: gene-outcome association.

 a)

 b)

Figure 2: Results of the MR on the effect of IPF on GERD risk using different robust

methods to address the issue of pleiotropy.

Figure 3: Identification of pleiotropic instruments in the MR on the effect of IPF on GERD. Individual variant contributions to Cochran's Q heterogeneity statistic with the 5th (dotted line) and Bonferroni corrected (0.05/19th) percentiles (dashed line) of a chi-squared with 1 degree of freedom.

References

1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198: e44–e68.

2. Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018;378: 1811–1823.

3. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest. 1998;113: 396–400.

4. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35: 496–504.

5. Pardo A, Selman M. The Interplay of the Genetic Architecture, Aging, and Environmental Factors in the Pathogenesis of Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2021;64: 163–172.

6. Prakash Gyawali C, Kahrilas PJ, Savarino E, Zerbib F, Mion F, Smout AJP, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67: 1351–1362.

7. Bédard Méthot D, Leblanc É, Lacasse Y. Meta-analysis of Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis. Chest. 2019;155: 33–43.

8.   Ghisa M, Marinelli C, Savarino V, Savarino E. Idiopathic pulmonary fibrosis and GERD: links and risks. Ther Clin Risk Manag. 2019;15: 1081–1093.

9.   Sifrim D, Holloway R. Transient lower esophageal sphincter relaxations: how many or how harmful? Am J Gastroenterol. 2001;96: 2529–2532.

10. Cheah R, Chirnaksorn S, Abdelrahim AH, Horgan L, Capstick T, Casey J, et al. The Perils and Pitfalls of Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis. Am J Gastroenterol. 2021;116: 1189–1200.

11. Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian Randomisation and Causal Inference in Observational Epidemiology. PLoS Medicine. 2008. p. e177. doi:10.1371/journal.pmed.0050177

12. Davey Smith G, Ebrahim S. "Mendelian randomization": can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32: 1–22.

13. Ong J-S, An J, Han X, Law MH, Nandakumar P, 23andMe Research team, et al. Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis. Gut. 2021 [cited 2 Sep 2021]. doi:10.1136/gutjnl-2020-323906

14. Allen RJ, Stockwell A, Oldham JM, Guillen-Guio B, Flores C, Noth I, et al. Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. bioRxiv. 2021. doi:10.1101/2021.12.06.21266509

15. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27: 1133–1163.

16. Li B, Martin EB. An approximation to the F distribution using the chi-square distribution. Comput Stat Data Anal. 2002;40: 21–26.

17. Noth I, Zhang Y, Ma S-F, Flores C, Barber M, Huang Y, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1: 309–317.

18. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013;45: 613–620.

19. Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med. 2017;5: 869–880.

20. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165: 277–304.

21. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official

ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183: 788–824.

22. Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158: 1804–1808.

23. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27: 136–142.

24. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46: 1113–1130.

25. GBD 2017 Gastro-oesophageal Reflux Disease Collaborators. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5: 561–581.

26. Raghu G. The role of gastroesophageal reflux in idiopathic pulmonary fibrosis. Am J Med. 2003;115 Suppl 3A: 60S–64S.

27. Savarino E, Carbone R, Marabotto E, Furnari M, Sconfienza L, Ghio M, et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J. 2013;42: 1322–1331.

28. Seibold MA, Smith RW, Urbanek C, Groshong SD, Cosgrove GP, Brown KK, et al. The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One. 2013;8: e58658.

29. Evans CM, Fingerlin TE, Schwarz MI, Lynch D, Kurche J, Warg L, et al. Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways. Physiol Rev. 2016;96: 1567–1591.

30. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, et al. Muc5b is required for airway defence. Nature. 2014;505: 412–416.

31. Kawar N, Park SG, Schwartz JL, Callahan N, Obrez A, Yang B, et al. Salivary microbiome with gastroesophageal reflux disease and treatment. Sci Rep. 2021;11: 188.

32. Hughes GW, Ridley C, Collins R, Roseman A, Ford R, Thornton DJ. The MUC5B mucin polymer is dominated by repeating structural motifs and its topology is regulated by calcium and pH. Sci Rep. 2019;9: 17350.

33. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA. Mucins in the mucosal barrier to infection. Mucosal Immunol. 2008;1: 183–197.

34. Molyneaux PL, Cox MJ, Willis-Owen SAG, Mallia P, Russell KE, Russell A-M, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190: 906–913.

35. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014;2: 548–556.

36. Houghton LA, Lee AS, Badri H, DeVault KR, Smith JA. Respiratory disease and the oesophagus: reflux, reflexes and microaspiration. Nat Rev Gastroenterol Hepatol. 2016;13: 445–460.

37. Noth I, Zangan SM, Soares RV, Forsythe A, Demchuk C, Takahashi SM, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2012;39: 344–351.

38. DiMarco AF, Kelsen SG, Cherniack NS, Gothe B. Occlusion pressure and breathing pattern in patients with interstitial lung disease. Am Rev Respir Dis. 1983;127: 425–430.

39. Khor YH, Bissell B, Ghazipura M, Herman D, Hon SM, Hossain T, et al. Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2022;19: 833–844.

40. Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole - Full Text View - ClinicalTrials.Gov. [cited 31 May 2022]. Available: https://clinicaltrials.gov/ct2/show/NCT04965298